Nov 10, 2025

Featuring perspectives from Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda, including the following topics: 

• Introduction (0:00)
• Localized Hormone Receptor (HR)-Positive Breast Cancer; Initial Therapy for Metastatic Disease — Dr Goetz (4:48)
• Relapsed/Refractory HR-Positive...

Nov 5, 2025

Featuring an interview with Prof Patrick Neven, including the following topics:

• Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00)
• Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57)
• Emerging data with novel oral SERD combinations (6:31)
• Challenges for a...

Nov 3, 2025

Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics:

• Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00)
• Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive,...

Oct 24, 2025

Featuring an interview with Dr Kevin Kalinsky, including the following topics:

• Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00)
  • Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on...

Oct 21, 2025

Featuring perspectives from Dr Aditya Bardia and Dr Adam M Brufsky, including the following topics:

• Introduction: Antibody-drug conjugates in localized breast cancer (0:00)
• Case: A frail woman in her late 70s with ER-positive, HER2-low metastatic breast cancer (mBC) receives sacituzumab govitecan after multiple lines...